EnergyRenewable Energy
Kalina Power Ltd

Kalina Power Ltd appoints new CEO in revised business strategy

au_boardoom_3_358_57f6e4bc255e0.jpg

Kalina Power Ltd (ASX:KPO) has appointed Ross MacLachlan as managing director and chief executive officer, keeping with the company’s revised business strategy.

Kalina is a power company that owns the Kalina Cycle® Technology.

The Kalina Cycle® Technology utilises waste heat generated from industrial processes, such as petrochemical, steel or cement making, to produce electricity.

The technology can also be used to generate power from renewable energy sources such as geothermal and solar thermal.

MacLachlan was recruited to Kalina by the company’s two largest investors in January 2015 and became integral to the company’s restructuring and development.

He has over 35 years experience in technology commercialisation and success in the renewable energy sector.

His appointment as CEO is in keeping with the company’s revised business strategy which includes the recruitment of senior executives to secure partnerships, preferred vendors and project financing for the deployment of the Kalina Cycle on an international scale. 

Kalina shares are up 20% over the past month, currently trading at $0.091.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Kalina Power Ltd

Price: $0.02

Market: ASX
Market Cap: $15.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Kazia Therapeutics reaches milestone for Phase 1 Cantrixil trial in ovarian...

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive Investors on a milestone for the company, with the completion of recruitment for Cantrixil its Phase 1 clinical trial in ovarian cancer. The CEO said the first part of the study has shown some very...

3 hours, 18 minutes ago

2 min read